Press Releases CervoMed Inc.

Equities

CRVO

US15713L1098

Market Closed - Nasdaq Other stock markets 21:00:00 23/05/2024 BST			5-day change	1st Jan Change
18.93 ^USD	-0.42%		-22.29%	+148.10%

05-20	CervoMed Names William Elder CFO	MT
05-15	Earnings Flash (CRVO) CERVOMED Posts Q1 Revenue $2.3M	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CervoMed to Appoint William Elder as Chief Financial Officer	05-20	AQ
CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates	05-15	AQ
CervoMed : Nominating and Corporate Governance Committee Charter	05-05	PU
CervoMed : Corporate Presentation April 2024	04-21	PU
CervoMed : Corporate Presentation April 2024	04-03	PU
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates	04-01	AQ
CervoMed to Participate in Upcoming Investor Conferences	03-28	AQ
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors	03-28	AQ
CervoMed : Shareholder Meeting - Form 8-K	03-18	PU
CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024	03-05	AQ
CervoMed to Participate in the BIO CEO and Investor Conference	02-21	AQ
CervoMed appoints drug development veteran Dr. Joshua Boger as Chairman of the Board	02-20	AQ
CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies	02-12	AQ
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board	02-07	AQ
CervoMed to Participate in the Emerging Growth Conference 67	02-05	AQ
CervoMed to Participate in the Emerging Growth Conference 66	01-05	AQ
CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies	26/10/23	AQ
CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias	25/10/23	AQ
CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies	19/10/23	AQ
CervoMed to Present at the 2023 Roth Healthcare Opportunities Conference	06/10/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases CervoMed Inc.

Equities

CRVO

US15713L1098

Press Releases

Filters